Patent SG-11201805557S-A (SG)
Title: Tetravalent anti-psgl-1 antibodies and uses thereof
Inventor: LIN RONG-HWA
IPC: A61K39/395
Filed: 2017-01-06
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111010111111011111111111101111011111 International Bureau 0.. .... .. ..... ..or::,,, (10) International Publication Number (43) International Publication Date WO 2017/120534 Al 13 July 2017 (13.07.2017) WI P0 I P CT (51) International Patent C07K 16/18 (2006.01) (21) International Application (22) International Filing (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/276,806 8 (71) Applicants: BIOALLIANCE weg 103, 1043 GP TERNATIONAL Highway, Dover, DE (72) Inventors: LIN, Rong-Hwa; Palo Alto, CA 94306 Lane 105, Lishan Street, Neihu District, Taipei, 114 (TW). — TSAI, Yu-Ying; 3f., No. 7 Alley 15, Lane 121, Jinghua Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/012621 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 6 January 2017 (06.01.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. January 2016 (08.01.2016) US (84) Designated States (unless otherwise indicated, for every C.V. [NL/NL]; Kingsford- kind of regional protection available): ARIPO (BW, GH, Amsterdam (NL). ABGENOMICS IN- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, INC. [US/US]; 3500 South Dupont TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 19901 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 4201 Juniper Lane Unit G, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (US). LIN, Shih-Yao; 7f., No. 1, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CL CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Taipei City, 116 (TW). Published: et al.; Morrison & Foerster LLP, — with international search report (Art. 21(3)) San Francisco, CA 94105-2482 (US). with sequence listing part of description (Rule 5.2(a)) — Street, Wenshan District, _ (74) Agents: JONES, Kevin = 425 Market Street, (54) Title: TETRAVALENT ANTI-PSGL-1 .....___ _ _ _ _ _...._ (1) 01, 2 -Fc = ANTIBODIES AND USES ....... (2) tafv z - Fc THEREOF (3) scFv-IgG antibodies, these (VL) domains and tetravalent antibodies can be used in diseases, trans - = — ' 3 Gs) , .6GSAAA CAp Fc to F c igGGGGS),AGGGGS),Gif (GGGGSOG herein are tetravalent antibodies that specifically bind to human PSGL-1. Unlike bivalent a dimer of two monomers, with each monomer comprising two light chain variable (VH) domains. This enhanced efficacy as compared to bivalent PSGL-1 antibodies. These tetravalent antibodies therapeutic methods, V2 - iG664), ASTGS C WS c 1/2-wl-?4pFc V4 .. GGGGS), ASTS5 V2 . SAM Gapic V4-V2-g4pFc FIG. including without , .. AiSAAA 1 _GGS), format allows for cross-linker/FcR-expressing cell-independent GGSGS NC x 3 a ,-,SGA 0 yy I 36GGS) 5 . scFv 2 -LC-IgG4p LC - sOY2 -1 11 64 P V2 i ;GGGSj s scFv 4 - 4p 1A limitation treating T-cell mediated inflammatory = — = = = = = _ 11 71' M ir) 0 ei 11 L ------ (57) : Provided ::::) tetravalent antibodies contain N two heavy chain variable O against PSGL-1 that show a variety of diagnostic and plantations, and transfusions.